In Section C, individuals will get ABBV-744 and oral navitoclax. In Section D, members will obtain ABBV-744 and ruxolitinib. Participants will receive treatment until eventually sickness progression or the participants are unable to tolerate the study drugs. Celastrol was recognized as being a Myb inhibitor that suppressed C/EBPβ exercise and https://abbv-744-safety-and-side46790.dailyhitblog.com/37394776/a-simple-key-for-abbv-744-for-targeted-cancer-therapy-treatment-unveiled